Navigation Links
Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
Date:12/16/2009

EVANSTON, Ill., Dec. 16 /PRNewswire/ -- Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor(1). The studies also showed that GLYX-13's antidepressant effects were evident within 20 minutes of administering a single dose and that it affected both the positive and negative symptoms of depression, while also demonstrating a lasting antidepressant effect. GLYX-13 is a glycine site functional partial agonist (GFPA) modulator of the NMDA receptor, a novel and selective mechanism discovered by Naurex scientists. GLYX-13 is initially being developed as a therapy for treatment-resistant depression. Separately, Naurex today announced that it has initiated a Phase I clinical trial to evaluate the safety of GLYX-13 in healthy volunteers.

"The NMDA receptor has long been a target for new treatments for CNS disorders, but the strong efficacy achieved by modulating the NMDA receptor has been accompanied by serious side effects such as schizophrenia-like symptoms, which has limited their use," said Ronald Burch, MD, PhD, chief medical officer at Naurex. "To overcome this problem, our founder Dr. Joseph Moskal used a unique approach to identify GLYX-13, a novel and selective modulator of the NMDA receptor. These new data demonstrate robust antidepressant activity by GLYX-13 with no signs of CNS side effects at any dose tested--an extraordinary early result. From a clinical perspective, we are also excited by the ability of GLYX-13 to alleviate both positive and negative symptoms of depression in these animal models, as well as by its very rapid onset o
'/>"/>

SOURCE Naurex Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 ... and manufacture of wireless personal healthcare products and ... its reach, announcing the release of two new ... blood pressure monitors and scales: the Wireless Pulse ... (Photo: http://photos.prnewswire.com/prnh/20130521/SF17618 ) ...
(Date:5/21/2013)...  Lehigh Valley Health Network has announced the deployment ... to its existing arsenal of five 5-foot-5 germ-killing UV ... the network, LVHN is now deploying the largest fleet ... and provide the best possible patient care available. ... – the signature product of Memphis ...
(Date:5/21/2013)... VIEW, Calif. , May 21, 2013  Healthcare ... , Russia , ... (BRIC) are realizing there are no shortcuts.  This is ... in the United States.  Companies must change the dialogue ... value, customizing to local needs, and building regional partnerships ...
Breaking Medicine Technology:iHealth Lab adds new products and partners to mobile personal healthcare offering 2iHealth Lab adds new products and partners to mobile personal healthcare offering 3Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4
... Calif. , Aug. 4 To combat the escalating ... New Momentum, the leading SaaS-based anti-counterfeiting solution.  Both companies expect that, ... violators, their New Momentum solution will play a key role in ... , , ...
... Cytel Inc., premier provider of adaptive clinical trial design services and software, recently ... studies based on frequentist or Bayesian methods. , ... The FDA,s recently issued adaptive trial guidelines draft encourages adaptive design ... , , ...
Cached Medicine Technology:Two More Global Pharmaceutical Companies Choose New Momentum to Stop Counterfeits 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 3
(Date:5/21/2013)... (PRWEB) May 21, 2013 Go Classy ... today that they have redesigned their website featuring ... beach, pool, hot tubs, bars and dining. The website, ... resort including sales and guest reviews, will now have ... Jamaica itself, including pages on culinary local recipes, flora ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
(Date:5/21/2013)... (HealthDay News) -- Aggressive treatment for prostate cancer ... with underlying medical conditions, a new study finds. ... radiation and radioactive seed implants, can cause serious ... and bowel problems, explained researchers from the University ... found that older patients with slower growing forms ...
(Date:5/21/2013)... for research and economic development will urge congressional ... of supercomputers designed to tackle complex societal questions, ... Daniel Reed will appear at a hearing on ... Energy, titled, "America,s Next Generation Supercomputer: The Exascale ... Room 2318 of the Rayburn House Office Building ...
(Date:5/21/2013)... 21 (HealthDay News) -- When a classmate commits suicide, ... themselves, according to a new study. This "suicide contagion" ... student personally, the researchers found. Teens aged 12 ... by Dr. Ian Colman, Canada Research Chair in Mental ... of Public Health. The study appeared May 21 in ...
Breaking Medicine News(10 mins):Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Iowa VP for Research addresses next-generation supercomputers at congressional hearing 2Health News:Student Suicide May Spur Similar Thoughts in Teens 2
... During the course of a hospitalization, patients are ... to the physician who has primary responsibility for ... details, illegibility, lost paperwork or other problems may ... implemented. , An award-winning study by Martin Were, ...
... Palomar Medical Technologies, Inc. (Nasdaq: PMTI ... for cosmetic treatments, announced today that it will unveil ... Optic(TM), LuxPowR(TM) pulsed-light handpiece and a more powerful Aspire ... of the American Academy of Dermatology (AAD) in San ...
... and Management,s History of Over-Promising & Under-Delivering Bodes ... The LCA-Vision Full Value Committee announced today ... the stockholders of LCA-Vision, Inc.: March 6, 2009Dear ... LCAV, with over 11% of the stock, we ...
... already at the heart of many management and prevention ... of the ESC Council on Cardiovascular Nursing and Allied ... complex needs of people with heart disease. "Of course, ... Deaton, "and we have seen heart disease rates decrease. ...
... Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical ... its Executive Chairman and Chief Executive Officer Mr. ... (SRA) 5th Annual Winter Technology Conference on Monday, ... Technology Conference, Mr. MacLellan will provide details of ...
... PowerPath(R) AP LIS to Interface with BioImagene,s ... March 6 Impac Software, part of ... software solutions for anatomic pathology (AP) laboratories, ... solutions, today announced the development of an ...
Cached Medicine News:Health News:Giving doctors the complete picture 2Health News:Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting 2Health News:Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting 3Health News:Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting 4Health News:Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting 5Health News:Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting 6Health News:The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo 2Health News:The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo 3Health News:The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo 4Health News:The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo 5Health News:Nurses and allied professionals at heart of cardiovascular prevention and management programs 2Health News:Nurses and allied professionals at heart of cardiovascular prevention and management programs 3Health News:AMDL, Inc. to Present at 5th Annual Winter Technology Conference Hosted by Security Research Associates, Inc. 2Health News:AMDL, Inc. to Present at 5th Annual Winter Technology Conference Hosted by Security Research Associates, Inc. 3Health News:Impac Software and BioImagene Develop Workflow Solution for Digital Pathology and the Laboratory Information Systems 2Health News:Impac Software and BioImagene Develop Workflow Solution for Digital Pathology and the Laboratory Information Systems 3
Disposable Microscissors: Horizontal, Curved...
Disposable Microscissors: Horizontal, Straight...
Disposable Microscissors: Vertical, 90...
Low profile, sharp-tipped scissors with a vertical cutting action. Excellent for peeling and cutting fine epiretinal membranes....
Medicine Products: